Member Info for goldust88

from iii Biome is only valued at just over £3million so is a tiddler, Just add up all the coffee cups used each day and the potentiall here is really huge. They have been working for some time with various companies to get the product perfect and the possibility for very large orders is imminent. If they get it right the share price wont stay at this level for long. I'm in. Could even be bought out by one of the big cup makers.

The only way is up at the moment with this share as buy back underway and no one wants to sell. Could be a very nice gain here in a relatively short time. 5000 shares traded and up 10%

Shares starting to move up as results near. With last nav at 272p this is cheap but this year they are valuing assets at current value -not cost as previous years. This could make a significant improvement to their net asset value, add in the divi and I expect a big leap in the share price up to and after results as currently way undervalued. In my view should be priced around the 240-250p mark.

iii comment More contracts announced-this looks good for the future with every click they get a payment -cant be bad with very little overhead per click. Could well expand into other countries as well as the US-world marketplace could be very big indeed. If they get it right ALT could really rocket as still really a shrimp in a big pond. Results soon lets see what they have to say .

From advfn Daz14 Apr '17 - 13:08 - 473 of 473 0 0 I attended a company presentation yesterday and found it very useful, here's a summary. Hopefully it will be of interest. The company is transitioning to a Software as a service (Saas) model, with 57% of revenues now coming from this source and which will increase further as a percentage this year. The order book stands at $23m, spread over a number of years and this provides substantial visibility of revenues both for this year and guarantees they will be profitable this year. Simulated learning is likely to grow significantly over the next 5 years as the Y and Z generation enter employment and it becomes more and more the norm, so the market opportunity for Simigon in the medium term is substantial. Learning by doing is also the most effective way to learn. Although the company has traditionally focused on military aviation, where there is a need to train pilots before they actually fly an aircraft, there are also other industries like oil and gas and crane operation where training for critical scenarios is vital and so there are many opportunities and they are working with resellers to expand these markets as being a small company, they don’t have the capability to do it themselves. The account receivables of $2.9m is due to the a number of factors :- the transition to the Saas model and the large contracts, a substantial amount of this has been collected since the year end. Cash flow was similarly affected and there should be an inflow this year. I came away thinking that given most of the market cap is covered by cash, there is a substantial opportunity here. Yes, the large contracts are going to be lumpy and unpredictable but the forecasts are conservative and don’t make allowance for any wins over the next few years. Given also that they have a substantial order book and a high level of visible recurring revenues, there is also not much risk and so you can play the long game and if they do gain the expected traction in new markets, then the price ought to substantially higher in a few years time.

RNS today says results above expectations with a few more major orders near be achieved. With the orders they have in hand this year they will be in serious profitability and with a very large workload already in the bag additional orders should see the share price race past last years high.

http://www.proactiveinvestors.co.uk/companies/stocktube/7019/potential-new-investment-recognises-the-underlying-value-in-igas-says-ceo-stephen-bowler-7019.html This was a month ago KEROGEN now 28% TRANS EUROPEAN O &G 13% so some big holders.

Moving up very nicely ,most investors seem to have missed the fact that the Indian stockmarket is doing extrmely well and set to do so for some time-asset avlue here over 110p and expected to narrow discount to near this.

My view is that they now have two sites now approved and ready for drilling one or both could be successful which would transform their prospects. Like any of these companies you can expect the share price to rise substantialy prior to the drilling taking place. The share price was currently at a low of 4.5p compared with a high of 18p in October so the rise has some way to go. They now have backing by Kerogen who are quite a clever bunch who know the business and I also expect Malcy to give some favourable comment as drilling nears. Whilst a lot of you may have lost a pile here times have now changed and this could well be a winner in the search for big UK gas. Look at Hurricane-10p a year ago-now 55p and could go much higher or Jersey Oil &Gas (Formerly Trap oil ) another multibagger-IGAS could rise just like them with a bit of luck. I don't expect any of the big holders to sell yet as the share price has much more to rise pre drilling and who would want to sell too early ? Its a buy for me

Bought in yesterday as way oversold-watch this get back to old highs the nearer the nearer the Nasdaq listing we get and more deals are announced.

Well my buy on the 21st was luckily on the button -with this new order and work in hand SRT will be in for a good year, if another order comes in we will be looking at a serious rise in share price.

Thanks for spotting that Toze-need a new calculator.

http://www.fool.co.uk/investing/2017/03/23/2-stocks-with-great-dividend-and-growth-potential/

from another board What is the future for Futura's share price. I have detailed below, from info in the results and more particularly from the webcast presentation (which not many may have seen-but now available on their website) what news Futura expects to announce during 2017, of which there is quite a lot. MED2000-Securing of major commercial deal. CSD500-Church & Dwight launch in selected markets(probably UK, France & Germany ) CSD500-Launch in 6 more countries and possibly up to 13. TPR100 & TIB200 -securing of further deals in USA/Europe. So what about the share price. Clearly there is massive potential if all the products end up all on sale at once but leading up to that point I think that announcements of each of the above this year will increase the share price as each one will confirm that progress is being made, some more than others. Clearly with any deal being announced one can expect upfront deal fees which can be substantial and this is what Futura expect as they stated at the results seminar they have no need to raise further cash. Looking at other company deals in these sectors the total upfront fees could easily be in the £25-40 million range. So what could Futura be worth in a couple of years time. From global sales figures provided by Futura we have the following peak potential for Futura's market share and earnings. MED 2000 ($1 billion per annum)= £800 million say @5% royalty is £40 million pa TPR100 & TIB200 (1/2 billion per annum)=£400 million say @5% royalty is £20 million pa CSD500 @10% market share of a $6billion pa market is $600 million=£450 million @ 5% royalty rate is £9 million per annum. That totals to £69 million per annum. That's the peak potential. Lets discount that by 1/2 that gives £34.5 million per annum. So with an income of that size with minimal overheads the company on a p/e of 8 would be valued at £552 million or 460p per share Current company value@53p is £63million So the potential is 9 times the current share price. With lots of news this year we could easily see the share price double up with the newsflow and big bucks coming after the MED 2000 trial results in a year or so. Price may drift a bit before the first news but as news may come at any time so it's a hold or buy at this price in my view. Also there may be a surprise announcement of a new product(s) as they are working on this at the moment.

I think that a lot of selling is end of tax year selling. The share price is down 50% from its high and the company is entering the second phase of their large contract which will generate much higher revenues that the first phase and then comes the big final phase in a years time. Also they still have a very large amount in the pipeline. With no news on these further contracts for quite a long time one could easily drop in in the coming weeks/months which would spring the share price into life. So for me now is the time to get in before these events occur.

Reading through todays RNS again I have noted that the potential is actually $1.6 billion. $ 1 billion for the over the counter market (OTC) PLUS $600 million for the prescription market. Why didn't they put that as the headline!

This is the bit I like in the RNS " the Company is continuing in negotiations to out-license the product." This report provides the evidence that big pharma want before they decide to do a deal on licensing-so these negotiations are ongoing at present-could well be a deal in the coming in the next few weeks and then see the share price move. Plus more launches of CSD 500 coming amd maybe the big one with Church & Dwight.

Iwould repeat my previous view for those interested--- COULD FUTURA’ SHARE PRICE RISE TO NEARER 325 p or more ?. I have done some research and calculations to determine what the share price should be if all goes ok FUTURA -Have six core products in the development pipeline for sexual healthcare and pain relief. They intend to licence out all of the products individually once they have reached a development and clinical approval stage that achieves best value. The company aims to achieve the highest licencing out value and then royalties. BUT HOW MUCH ARE THE PAIN RELIF PRODUCTS WORTH ? SPR300, together with TPR100 and TIB200, presents a portfolio opportunity for a potential licensing partners A crossover clinical study has recently been carried out to assess the efficacy and safety of TIB200 against a market-leading ibuprofen gel, against orally delivered ibuprofen and against a placebo of TIB200's gel, TIB200 achieved its primary endpoint and presents an exciting product opportunity. No comparator product, topical or oral pain relief product outperformed TIB200. SPR300--.SPR300 is a topical gel combining methyl salicylate and menthol with the DermaSys delivery system. SPR300 has been shown to achieve in excess of four times higher penetration through isolated human skin compared with the UK's best-selling topically applied methyl salicylate/menthol-based topical pain relief product, Deep Heat. . Doing some research I found this info on what licencing fees were paid for voltoral-the main pain relief gel available at the moment. (March 2008 -Endo Pharmaceuticals has entered into a licensing agreement with Novartis to obtain the exclusive US marketing rights for the prescription medicine Voltaren Gel (diclofenac sodium topical gel) 1%. Under the terms of the five-year agreement with Novartis, Endo will make an upfront cash payment of $85 million. (£63 million) plus royalties. Novartis is also eligible to receive a one-time milestone payment of $25 million if annual sales exceed $300 million. ) So just for the US rights a fee of £63 million was paid plus royalties. Its possible that Futura’s pain products could command a similar amount. If we add the pain portfolio value ( say just for the US only)) of £63 million upfront PLUS for the erection Gel an upfront payment of the same amount ,£63 million. This Totals £126 MILLION UP FRONT FEES. After that we have the royalty payments for Gel ( a 5% royalty per annum on $ Billion of sales is $50 million equals £ 37.5 million per annum and lets say for the Pain portfolio only 12.5 million per annum. THATS PLUS A TOTAL OF £50 MILLION PER ANNUM INCOME.. The upfront licencing fees alone would give a share price of about 125 p and with the royalty income it SUGGESTS A SHARE PRICE REACHING 625p.,but lets discount that by about half-SAY 325p A SHARE. Work it out for yourself.

(full text version) COULD FUTURA’ SHARE PRICE RISE TO NEARER 325 p or more ?. I have done some research and calculations to determine what the share price should be if all goes ok FUTURA -Have six core products in the development pipeline for sexual healthcare and pain relief. They intend to licence out all of the products individually once they have reached a development and clinical approval stage that achieves best value. The company aims to achieve the highest licencing out value and then royalties. BUT HOW MUCH ARE THE PAIN RELIF PRODUCTS WORTH ? SPR300, together with TPR100 and TIB200, presents a portfolio opportunity for a potential licensing partners A crossover clinical study has recently been carried out to assess the efficacy and safety of TIB200 against a market-leading ibuprofen gel, against orally delivered ibuprofen and against a placebo of TIB200's gel, TIB200 achieved its primary endpoint and presents an exciting product opportunity. No comparator product, topical or oral pain relief product outperformed TIB200. SPR300--.SPR300 is a topical gel combining methyl salicylate and menthol with the DermaSys delivery system. SPR300 has been shown to achieve in excess of four times higher penetration through isolated human skin compared with the UK's best-selling topically applied methyl salicylate/menthol-based topical pain relief product, Deep Heat. . Doing some research I found this info on what licencing fees were paid for voltoral-the main pain relief gel available at the moment. (March 2008 -Endo Pharmaceuticals has entered into a licensing agreement with Novartis to obtain the exclusive US marketing rights for the prescription medicine Voltaren Gel (diclofenac sodium topical gel) 1%. Under the terms of the five-year agreement with Novartis, Endo will make an upfront cash payment of $85 million. (£63 million) plus royalties. Novartis is also eligible to receive a one-time milestone payment of $25 million if annual sales exceed $300 million. ) So just for the US rights a fee of £63 million was paid plus royalties. Its possible that Futura’s pain products could command a similar amount. If we add the pain portfolio value ( say just for the US only)) of £63 million upfront PLUS for the erection Gel an upfront payment of the same amount ,£63 million. This Totals £126 MILLION UP FRONT FEES. After that we have the royalty payments for Gel ( a 5% royalty per annum on $ Billion of sales is $50 million equals £ 37.5 million per annum and lets say for the Pain portfolio only 12.5 million per annum. THATS PLUS A TOTAL OF £50 MILLION PER ANNUM INCOME.. The upfront licencing fees alone would give a share price of about 125 p and with the royalty income it SUGGESTS A SHARE PRICE REACHING 625p.,but lets discount that by about half-SAY 325p A SHARE. Work it out for yourself.

COULD FUTURA’ SHARE PRICE RISE TO NEARER 310 p IN THE NEXT YEAR-or more ?. I have done some research and calculations to determine what the share price should be if all goes ok FUTURA -Have six core products in the development pipeline for sexual healthcare and pain relief. They intend to licence out all of the products individually once they have reached a development and clinical approval stage that achieves best value. The company aims to achieve the highest licencing out value and then royalties. Futura has sufficient funds to achieve this so no fund raising is considered necessary. The possible income only ( let alone licencing agreement upfront fee) from the gel is @ £37.5 Million per annum. BUT HOW MUCH ARE THE PAIN RELIF PRODUCTS WORTH ? SPR300, together with TPR100 and TIB200, presents a portfolio opportunity for a potential licensing partners A crossover clinical study has recently been carried out to assess the efficacy and safety of TIB200 against a market-leading ibuprofen gel, against orally delivered ibuprofen and against a placebo of TIB200's gel, TIB200 achieved its primary endpoint and presents an exciting product opportunity. No comparator product, topical or oral pain relief product outperformed TIB200. SPR300--.SPR300 is a topical gel combining methyl salicylate and menthol with the DermaSys delivery system. SPR300 has been shown to achieve in excess of four times higher penetration through isolated human skin compared with the UK's best-selling topically applied methyl salicylate/menthol-based topical pain relief product, Deep Heat.. Doing some research I found this info on what licencing fees were paid for voltoral-the main pain relief gel available at the moment. (March 2008)Endo Pharmaceuticals has entered into a licensing agreement with Novartis to obtain the exclusive US marketing rights for the prescription medicine Voltaren Gel (diclofenac sodium topical gel) 1%. Endo estimates US peak annual sales for Voltaren Gel as an osteoarthritis pain treatment in the range of $250-300 million. Under the terms of the five-year agreement with Novartis, Endo will make an upfront cash payment of $85 million. (£63 million) plus royalties. Novartis is also eligible to receive a one-time milestone payment of $25 million if annual sales exceed $300 million. ) So just for the US rights a fee of £63 million was paid plus royalties.Its possible that Futura’s pain products could command a similar amount.If we add the pain portfolio value ( say just for the US only)) of £63 million upfront PLUS for the erection Gel an upfront payment of the same amount ,£63 million. This Totals £126 MILLION UP FRONT FEES. After that we have the royalty payments for Gel ( a 5% royalty per annum on $ Billion of sales is $50 million equals £ 37.5 million per annum and lets say for the Pain portfolio only £12.5 million per annum. THATS PLUS A TOTAL OF £50 MILLION PER ANNUM INCOME..